Life Sciences

  • June 02, 2026

    Generics Makers Tell 3rd Circ. Buyers Too Few For Class

    Two pharmaceutical companies embroiled in decadelong litigation over the alleged price-fixing of generic drugs told a Third Circuit panel on Tuesday that groups of drug buyers either didn't have the numbers necessary to support class certification or were not clearly identifiable.

  • June 02, 2026

    FTC Sues Supplement Co. Over Mental Health, Income Claims

    The Federal Trade Commission on Tuesday sued dietary supplement brand Amare Global Holdings Inc. in California federal court, alleging it misleads buyers by falsely claiming its products can treat mental health issues, while also misleading prospective "brand partners" about how much they are likely to make under Amare's program.

  • June 02, 2026

    DLA Piper Brings On A&O Shearman M&A Partner In SF

    DLA Piper has announced it is pushing forward with its "strategic expansion" in Northern California with the addition of "a market-leading dealmaker" from Allen Overy Shearman Sterling.

  • June 02, 2026

    Pharma Co. Inks $7M Deal To End Investor's Cancer Study Suit

    A Spectrum Pharmaceuticals Inc. investor has asked a New York federal court to approve a $7 million deal resolving class action claims alleging the drugmaker overstated its regulatory prospects for winning approval for a cancer treatment.

  • June 02, 2026

    Judge Ends Nausea Drug Suit After Invalidating Other Patents

    A federal judge has ruled one set of patents covering the nausea drug Cinvanti was invalid and found a set asserted in another suit not infringed.

  • June 02, 2026

    Lack Of Indemnity Liability Doomed Vax IP Case, Judge Says

    Drug developer Acuitas Therapeutics Inc. failed to show that it would have to indemnify BioNTech as a result of GlaxoSmithKline's patent infringement lawsuit against BioNTech and Pfizer over the COVID-19 vaccine, a Delaware federal judge has said.

  • June 02, 2026

    Chinese Protein Testing Tech Infringes US Patents, Co. Says

    A U.S. biotechnology company told the U.S. International Trade Commission that a Chinese company is importing and selling kits and other technology in the U.S. that infringe patents related to testing the proteins in genomes, and requested that the products be banned from entering the country.

  • June 01, 2026

    3rd Circ. Preview: AI Copyright Spat, NJ Gun Law Battle

    A copyright fight over the future of AI‑powered legal research heads to the Third Circuit, where a legal publisher will argue this month that a legal technology company's use of its headnotes does not constitute fair use of copyrighted material. The court will also take up a challenge to New Jersey's firearm nuisance law in a case that asks when a trade group can bring a federal suit over a state statute.

  • June 01, 2026

    Albertsons Had Duty To Curb Opioid Diversion, Judge Rules

    As providers of controlled substances, pharmacy giants Albertsons and Safeway had legal duties to prevent the diversion of opioid drugs, a Washington state judge ruled on Monday, though whether the companies failed to fulfill those duties will be determined at trial.

  • June 01, 2026

    Justices Say 11th Circ. Wrong To Consider Posttrial DNA Test

    The U.S. Supreme Court on Monday vacated an Eleventh Circuit opinion that denied habeas relief to a Florida man on death row, saying the appellate court erroneously considered a posttrial DNA analysis that was never seen by the jurors who convicted him.

  • June 01, 2026

    'We Wouldn't Be Alive' If Talc Could Reach Ovaries, Jury Told

    A University of California San Diego gynecologic oncologist told a California jury Monday in a bellwether trial over claims that Johnson & Johnson's talc products caused three women's deadly ovarian cancer that women and girls "wouldn't be alive" if talc could easily migrate to the ovaries because they'd be dying from sepsis.

  • June 01, 2026

    Valeant Investors Should Get Cert. In PwC Fight, Report Says

    A special master recommended Monday that a New Jersey federal judge certify a class of Valeant Pharmaceuticals stockholders looking to hold PwC liable for missing "red flags" that could have caught what they called market manipulation by the pharmaceutical company, rejecting the professional services giant's argument that the lead plaintiff's claims are atypical and "lawyer-driven."

  • June 01, 2026

    11th Circ. Won't Stop Joint Hearing In Depo-Provera MDL

    A group of Delaware plaintiffs who say Pfizer's hormonal contraceptive Depo-Provera causes brain tumors can't block a joint evidentiary hearing with a Florida federal court overseeing multidistrict litigation over the same claims after the Eleventh Circuit denied their petition Monday.

  • June 01, 2026

    Moderna Tells Fed. Circ. US Must Face COVID Vax Patent Case

    Moderna has urged the Federal Circuit to rule that Arbutus Biopharma must pursue its patent infringement claims over Moderna's COVID-19 vaccine against the U.S. government, saying a lower court ruling that Moderna must face the multibillion-dollar suit was "deeply flawed."

  • June 01, 2026

    Garmin's Smart Scale Uses Estimates In Readings, Suit Says

    Garmin has been hit with proposed class consumer fraud claims by an Illinois customer who says the company illegally misrepresents that its Index smart scale can accurately measure someone's body composition.  

  • June 01, 2026

    Judge Trims Dental Patent Case, But Keeps Patent Alive

    A Delaware federal judge has refused to invalidate a pair of dental patents that medical technology companies Align Technology and Medit Corp. were accused of infringing, but did agree to narrow the case.

  • June 01, 2026

    Plaintiffs' Counsel In Tylenol MDL Agree To $50K Donation

    A plaintiffs' attorney and law firm sanctioned in multidistrict litigation alleging prenatal exposure to acetaminophen can cause autism agreed to donate $50,000 to maternal health organization March of Dimes in lieu of paying attorney fees, according to a letter filed Monday in New York federal court. 

  • June 01, 2026

    NC Biz Court Bulletin: Referee Tapped, CEO To Be Deposed

    The North Carolina Business Court rounded out May by appointing a discovery referee in a healthcare antitrust class action and ordering the deposition of a top executive in a trade secrets battle, in addition to fielding a new complaint alleging unpaid capital contributions for a captive insurance company.

  • June 01, 2026

    US Trade Officials Open IP Probe Into Vietnam

    U.S. trade officials have launched an investigation into Vietnam over what they said were concerns about how the country is allegedly not effectively protecting the rights of intellectual property owners.

  • June 01, 2026

    La. Sends Psychedelic Therapy Research Bill To Governor

    Louisiana lawmakers have given final approval to a bill to establish a psychedelic-assisted therapy program under the state's health department.

  • June 01, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court this past week handled disputes involving merger litigation, startup financing battles, cryptocurrency contracts, investor oversight claims and corporate governance challenges, while also issuing notable rulings in cases tied to World Wrestling Entertainment Inc., cybersecurity company KnowBe4 Inc. and biotechnology firm Ayala Pharmaceuticals Inc.

  • June 01, 2026

    Justices Skip CareDx's Bid To Revive $45M False Ad Award

    The U.S. Supreme Court on Monday declined to take up a challenge to a Third Circuit decision that wiped out a nearly $45 million false advertising award against Natera Inc., preserving a ruling that said proof of actual consumer deception is required to support damages.

  • May 29, 2026

    Illumina Ducks DNA Sequence Rival's Antitrust Suit, For Now

    A DNA sequencing startup will have to rejigger its antitrust lawsuit against Illumina after a California federal judge said it hasn't shown that the industry giant has entered exclusive agreements and hasn't adequately asserted that Illumina priced its offerings below cost, among other failings.

  • May 29, 2026

    Justices Told USPTO's 'Settled Expectations' Rule Flouts Law

    A host of industry groups, professors, attorneys and more urged the U.S. Supreme Court on Friday to take up Google's appeal arguing that the U.S. Patent and Trademark Office has exceeded its authority by using the age of patents as a reason to refuse to review them.

  • May 29, 2026

    Ohio AG Says Cigna Can't Use Sherman Act To Ax State Case

    The Ohio attorney general has urged a federal judge not to dismiss prescription drug price-fixing claims against Express Scripts, its Cigna parent and fellow pharmacy benefit manager Prime Therapeutics, arguing the companies are trying to fight his state law antitrust claims by invoking federal law standards that do not apply.

Expert Analysis

  • The Benefits Of Choosing A Niche Practice In The AI Age

    Author Photo

    As artificial intelligence becomes increasingly accessible, lawyers with a niche practice may stand out as clients seek specialized judgment that automation cannot replicate, but it is important to choose a niche that is durable, engaging and a good personal fit, says Daniel Borneman at Lowenstein Sandler.

  • How PBMs Can Adapt To Plan Sponsors' Disclosure Demands

    Author Photo

    As federal reforms, growing state regulation and litigation threats push plan sponsors to expect visibility into revenue streams, pharmacy benefit managers should leverage transparency strategically, including by simplifying how they get paid, offering clients audit-ready data and co-designing contracts that are easy for fiduciaries to explain and defend, says Kristie Blase at Frazer + Blase.

  • What New Animal Welfare Enforcement Push Means For Cos.

    Author Photo

    The Trump administration's recently announced multiagency focus on violations of the Animal Welfare Act and related laws will likely lead to broader enforcement actions across industries, heightened scrutiny of compliance standards and a need for businesses to adopt effective risk management practices, says Shennie Patel at Crowell & Moring.

  • How To Engage With Gov't's Direct-To-Consumer Drug Policy

    Author Photo

    The U.S. Department of Health and Human Services' recent request for industry input on manufacturers' direct-to-consumer drug sales reflects the government's caution in this arena, and allows stakeholders a rare opportunity to help shape policy, says Mary Kohler at Kohler Health Law.

  • Series

    Podcasting Makes Me A Better Lawyer

    Author Photo

    Podcasting has changed how I ask questions and connect with people, sharpening my ability to listen without interrupting or prejudging, and bringing me closer to what law is meant to be: a human profession grounded in understanding, judgment and trust, says Donna DiMaggio Berger at Becker.

  • Patent Eligibility Bulletin: Steps To Consider As USPTO Shifts

    Author Photo

    Recent memoranda from the U.S. Patent and Trademark Office, along with some of the first patents issued under Director John Squires, indicate a recalibration of the subject matter eligibility landscape, signaling a renewed emphasis on concrete technological improvements and a potentially pro-AI stance, say attorneys at Banner Witcoff.

  • Tax Court Ruling Signals Cross-Border Loan Scrutiny

    Author Photo

    The U.S. Tax Court’s recent decision in Aventis v. Commissioner compounds ongoing regulatory focus on debt originations and should prompt practitioners to assess their existing cross-border lending structures for potential exposure to U.S. federal income tax, say attorneys at Eversheds.

  • Lessons From Justices' Split On Major Questions Doctrine

    Author Photo

    The justices' varied opinions in Learning Resources v. Trump, which held the International Emergency Economy Powers Act did not confer the power to impose tariffs, offer a meaningful window into the U.S. Supreme Court's perspective on the major questions doctrine that will likely shape lower courts' approach to executive action challenges, say attorneys at Venable.

  • Drug Wholesaler's DPA Shows Imperfect Efforts Still Count

    Author Photo

    Atlantic Biologicals’ recent deferred prosecution agreement with federal prosecutors for allegedly distributing controlled substances to pill mill pharmacies demonstrates that even subpar cooperation, when combined with genuine remediation and strategic advocacy, can yield outcomes that protect a company's long-term interests, says Jonathan Porter at Husch Blackwell.

  • Key Takeaways As HRSA Aims To Revive 340B Rebate Pilot

    Author Photo

    The U.S. Department of Health and Human Services' recent request for feedback on the 340B Rebate Model Pilot Program demonstrates that it intends to correct the model's procedural defects, which is positive news for participating manufacturers, but a setback for covered entities, say attorneys at Manatt.

  • When MDLs Drag, State Courts Can Speed Mass Tort Results

    Author Photo

    Understanding the structural dynamics that can delay resolution in multidistrict litigation is essential to understanding why a state court strategy is sometimes not merely attractive, but necessary for plaintiffs seeking timely and just outcomes, say attorneys at DiCello Levitt.

  • Leveraging MDLs And State Courts In Mass Tort Strategy

    Author Photo

    Multidistrict litigation's quiet drift from a pretrial coordination device to a de facto national court for mass torts poses a strategic question for plaintiffs counsel — whether an MDL will yield timely trials, meaningful accountability and fair value for clients, or whether a state court strategy will be more effective, say attorneys at DiCello Levitt.

  • Unique Issues Facing Brand-Compounder Patent Litigation

    Author Photo

    Recent litigation and potential enforcement action against Hims & Hers Health raise questions about how compounders and branded pharmaceuticals companies would be positioned in patent litigation as compared to generics companies, which would require strategies different from those that would be used in traditional Hatch-Waxman Act litigation, say attorneys at Morgan Lewis.

  • Series

    Volunteering With Scouts Makes Me A Better Lawyer

    Author Photo

    Serving as an assistant scoutmaster for my son’s troop reaffirmed several skills and principles crucial to lawyering — from the importance of disconnecting to the value of morality, says Michael Warren at McManis Faulkner.

  • Series

    Law School's Missed Lessons: In Court, It's About Storytelling

    Author Photo

    Law school provides doctrine, cases and hypotheticals, but when lawyers step into the courtroom, they must learn the importance of clarity, credibility, memorability and preparation — in other words, how to tell simple, effective stories, say Nicholas Steverson and Danielle Trujillo at Wheeler Trigg, and Lisa DeCaro at Courtroom Performance.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.